Cipher Pharmaceuticals Inc. - Third Quarter 2026 Financial Results Call - CIPHER PHARMACEUTICALS INC

Explicit Guidance:

• None provided by management; the transcript focuses on historical Q3 2026 results and strategic priorities without issuing specific numerical forward-looking ranges for revenue, earnings, or margins.

Business-Segment Outlook:

• Natroba (U.S.): Expects sequential improvement in revenue momentum (14% sequential increase in Q3 2026) to continue; plans to expand beyond Medicaid via commercial payers, direct-to-patient, and retail pharmacy channels with increased selling/marketing spend to drive awareness.
• Natroba (International): Anticipates results from Health Canada's new drug submission for head lice and scabies "soon and likely in the first quarter of 2027"; identifies unmet need in Canada and global markets due to permethrin resistance.
• EPURIS (Canada): Expects expanded public drug plan coverage (now effective in BC, Quebec, Alberta) to "continue contributing to market share growth over time"; projects continued sales growth driven by wider patient access and increased sales/marketing initiatives.
• Arbitration Royalty: A 15% royalty on net sales of Zorica LD (Canada) is effective January 1, 2026, and runs through the end of 2040; represents a long-term revenue stream not yet fully recognized in results.

Market and Competitive Outlook:

• U.S. Head Lice/Scabies: Management believes permethrin 5% is "clearly superior" to existing options for scabies and that head lice market share will shift toward Natroba as consumers/prescribers recognize treatment failures with OTC permethrin 1%.
• U.S. Medicaid: Acknowledges ongoing headwinds from reduced Medicaid covered lives but notes strong utilization in states like Illinois, with annual/bi-annual renewal negotiations expected to maintain coverage.
• Canadian Acne: EPURIS maintains leadership position (48.7% market share as of Sept 30, 2026) with projected share expansion as public coverage deepens in key jurisdictions.
• Competitive Positioning: Views Natroba as a "proven single treatment option" addressing unmet needs globally; notes competitors' products are becoming "less effective due to resistance."

Macro / Industry Outlook:

• Regulatory/Tariffs: No specific commentary on macroeconomic rates, FX, or broad regulation, other than the positive impact of Health Canada's acceptance of Netroba submission.
• Sector Dynamics: Anticipates continued resistance to standard treatments (permethrin) driving demand for superior alternatives like Natroba in both U.S. and international markets.

Strategic Initiatives:

• M&A and BD: Three-pronged strategy: (1) Acquire/in-license complementary products for U.S. and Canadian commercialization; (2) Out-license Natroba and EPURIS to non-North American markets; (3) Pursue company acquisitions for strategic scale.
• Execution Timeline: Management expects to close a transaction "in the short term," though specific dates are withheld to avoid vendor leverage. Priority is given to U.S. product expansion, with Canada as secondary.
• Capital Allocation: Considering a Substantial Issuer Bid (SIB) to replace or augment the current restrictive Normal Course Issuer Bid (NCIB) for share buybacks; will prioritize acquisitions/deals over buybacks if deals are imminent.
• Licensing Partnerships: Discussions ongoing with Sun Pharmaceuticals regarding an Absorica (U.S.) extension and evaluating proposals from other generic manufacturers; no timeline specified.
• Talent: Board expanded with Rajiv De Silva to strengthen M&A execution and corporate strategy capabilities.

Risks and Headwinds to Outlook:

• Medicaid Volume: Continued reductions in Medicaid covered lives pose a risk to U.S. Natroba revenue growth.
• M&A Uncertainty: Deal timelines are variable; opportunities may not materialize, and advanced-stage discussions may not result in transactions.
• Competitive Behavior: In the U.S. head lice market, significant consumer inertia toward OTC permethrin products could delay Natroba adoption rates.
• Payer Restrictions: Medicaid step-through requirements vary by state and clinical committee, creating uncertainty in coverage renewals.

Management Tone on the Future:

• Confidence: High confidence in the "proven" efficacy of Natroba and EPURIS; optimistic about finding acquisition opportunities "in the short term."
• Stability: Emphasizes a "debt-free" balance sheet and strong cash generation ($15.3M cash at quarter-end, growing to ~$20M post-arbitration proceeds) as a foundation for strategic investments.
• Cautious Optimization: Willing to pause buybacks to prioritize deal execution; maintains that the NCIB is too restrictive, signaling a shift toward more aggressive capital deployment mechanisms.

Miscellaneous:

• Arbitration Impact: One-time net income boost of $10.9M in Q3 2026 (including $2.3M damages, $2.2M fee recovery, $0.5M interest) excluded from adjusted EBITDA; $5.7M cash collected subsequent to quarter-end.
• Financial Metrics: Projected to maintain high profitability with gross margins around 81% and adjusted EBITDA margins near 58% on a year-to-date basis, barring significant macro shifts.
• Cash Liquidity: Retains $65M undrawn availability on existing facility plus a $25M accordion feature, providing flexibility for growth strategy funding.